TY - JOUR
T1 - Metastatic type 1 gastric carcinoid
T2 - A real threat or just a myth?
AU - Grozinsky-Glasberg, Simona
AU - Thomas, Dimitrios
AU - Strosberg, Jonathan R.
AU - Pape, Ulrich Frank
AU - Felder, Stephan
AU - Tsolakis, Apostolos V.
AU - Alexandraki, Krystallenia I.
AU - Fraenkel, Merav
AU - Saiegh, Leonard
AU - Reissman, Petachia
AU - Kaltsas, Gregory
AU - Gross, David J.
PY - 2013/12/14
Y1 - 2013/12/14
N2 - AIM: To describe disease characteristics and treatment modalities in a group of rare patients with metastatic gastric carcinoid type 1 (GCA1). METHODS: Information on clinical, biochemical, radiological, histopathological findings, the extent of the disease, as well as the use of different therapeutic modalities and the long-term outcome were recorded. Patients' data were assessed at presentation, and thereafter at 6 to 12 monthly intervals both clinically and biochemically, but also endoscopically and histopathologically. Patients were evaluated for the presence of specific symptoms; the presence of autoimmune disorders and the presence of other gastrointestinal malignancies in other family members were also recorded. The evaluation of response to treatment was defined using established WHO criteria. RESULTS: We studied twenty consecutive patients with a mean age of 55.1 years. The mean follow-up period was 83 mo. Twelve patients had regional lymph node metastases and 8 patients had liver metastases. The primary tumor mean diameter was 20.13 ± 10.83 mm (mean ± SD). The mean Ki-67 index was 6.8% ± 11.2%. All but one patient underwent endoscopic or surgical excision of the tumor. The disease was stable in all but 3 patients who had progressive liver disease. All patients remained alive during the follow-up period. CONCLUSION: Metastatic GCA1 carries a good overall prognosis, being related to a tumor size of ≥ 1 cm, an elevated Ki-67 index and high serum gastrin levels.
AB - AIM: To describe disease characteristics and treatment modalities in a group of rare patients with metastatic gastric carcinoid type 1 (GCA1). METHODS: Information on clinical, biochemical, radiological, histopathological findings, the extent of the disease, as well as the use of different therapeutic modalities and the long-term outcome were recorded. Patients' data were assessed at presentation, and thereafter at 6 to 12 monthly intervals both clinically and biochemically, but also endoscopically and histopathologically. Patients were evaluated for the presence of specific symptoms; the presence of autoimmune disorders and the presence of other gastrointestinal malignancies in other family members were also recorded. The evaluation of response to treatment was defined using established WHO criteria. RESULTS: We studied twenty consecutive patients with a mean age of 55.1 years. The mean follow-up period was 83 mo. Twelve patients had regional lymph node metastases and 8 patients had liver metastases. The primary tumor mean diameter was 20.13 ± 10.83 mm (mean ± SD). The mean Ki-67 index was 6.8% ± 11.2%. All but one patient underwent endoscopic or surgical excision of the tumor. The disease was stable in all but 3 patients who had progressive liver disease. All patients remained alive during the follow-up period. CONCLUSION: Metastatic GCA1 carries a good overall prognosis, being related to a tumor size of ≥ 1 cm, an elevated Ki-67 index and high serum gastrin levels.
KW - Chromogranin A
KW - Gastrin
KW - Metastatic gastric carcinoids
KW - Somatostatin analogues
KW - Stomach neuroendocrine tumor
UR - http://www.scopus.com/inward/record.url?scp=84890346543&partnerID=8YFLogxK
U2 - 10.3748/wjg.v19.i46.8687
DO - 10.3748/wjg.v19.i46.8687
M3 - Article
C2 - 24379587
AN - SCOPUS:84890346543
VL - 19
SP - 8687
EP - 8695
JO - World Journal of Gastroenterology
JF - World Journal of Gastroenterology
SN - 1007-9327
IS - 46
ER -